Kreaxi
  • Home
  • Company
  • Funds
  • Team
  • Portfolio
  • News
  • Contact
  • Français
Select Page
REGION AUVERGNE-RHONE-ALPES

REGION AUVERGNE-RHONE-ALPES

REGION...
BPI FRANCE

BPI FRANCE

BPI...
CREDIT AGRICOLE

CREDIT AGRICOLE

CREDIT...
CAISSE D’EPARGNE

CAISSE D’EPARGNE

CAISSE...
BNP PARIBAS

BNP PARIBAS

BNP...
« Older Entries

Recent Posts

  • Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.
  • Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
  • Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
  • Amolyt Pharma announces research collaboration with PeptiDream
  • The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF

Recent Comments

    Archives

    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • July 2020
    • April 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • July 2019
    • March 2019
    • February 2019
    • December 2018
    • November 2018
    • December 2017
    • September 2017
    • April 2017

    Categories

    • News portfolio

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    Kreaxi is an investment management firm specialized in the equity financing of innovative and tech startups with high growth potential. Kreaxi manages regional funds, active in Auvergne-Rhône-Alpes (80M€) as well as national funds (180M€).

    Lyon

    101, Chemin Vert
    69760 Limonest 
    France

    +33 4 72 52 39 39

    Paris

    13-15 rue Taitbout
    75009 Paris
    France

    +33 1 73 02 89 69

    • Twitter
    © 2019 Kreaxi. Tous droits réservés. Mentions légales. Informations réglementaires. Démarche ESG.